predicting treatment response. A paclitaxel ML signature based on tumor gene 9 9 expression had a higher success predicting the pathological complete response rate 1 0 0 (pCR 18 ) for sensitive patients (84% of patients with no / minimal residual disease) than 1 0 1 models based on differential gene expression (GE) analysis 6 . For gemcitabine, a 1 0 2 signature derived from both expression and copy number (CN) data from breast cancer 1 0 3 cell lines was derived, and subsequently applied to analysis of nucleic acids from patient 1 0 4 archival material. Multiple other outcome measures used to validate gene signatures 1 0 5 include prognosis 5 , Miller-Payne response 19 , and disease recurrence. Binary SVM 1 0 6 classifiers based on discrete time thresholds have been used to classify continuous 1 0 7 outcome measures such as prognosis and recurrence. By contrast, pCR is simpler to 1 0 8 interpret with binary SVM models. Nevertheless, differences in clinical recurrence have 1 0 9 been noted between patients demonstrated with pCR and those who do not exhibit 1 1 0 disease pathology 18 . This source of variability in defining patient response can confound 1 1 1 transferability of SVM models between different datasets. 1 1 2
We apply biochemically-inspired ML to predict and compare the cellular and 1 1 3 patient responses to cisplatin, carboplatin and oxaliplatin. We train models for 1 1 4 classification of platin resistance with cancer cell line data and validate with patient GE 1 1 5 and outcome data. Our previous gene signatures were based on median GI 50 for each 1 1 6 drug 6 . This has been a necessary compromise, however in this study we consider 1 1 7 signatures that differ at the highest vs. the lowest levels of drug resistance. A series of 1 1 8 gene signatures are derived by shifting the GI 50 thresholds that distinguish sensitivity 1 1 9 from resistance. The frequency of genes selected at median vs. extreme thresholds 1 2 0 highlights pathways that define these responses among different patient subsets. 1 2 1 1 2 2 RESULTS 1 2 3
Selection of Platin Drug Related Genes 1 2 4
We documented genes in the peer-reviewed literature associated with drug 1 2 5 effectiveness or response (Supplemental References). For cisplatin, carboplatin and 1 2 6 oxaliplatin, this implicated 178, 90, and 288 genes, respectively (Suppl . Table S1 ). 1 2 7
Multiple factor analyisis (MFA) was used to determine which genes were correlated to 1 2 8 GI 50 in breast cancer cell lines through either GE and/or CN 13 , significantly reducing the 1 2 9 sizes of the gene sets for cisplatin (N=39), carboplatin (N=28), and oxaliplatin (N=55). 1 3 0
Genes with significant relationships to GI 50 and direction of correlation (positive or 1 3 1 inverse) are indicated in Figure 1 . The diverse functions of these genes included 1 3 2 apoptosis, DNA repair, transcription, cell growth, metabolism, immune system, signal 1 3 3 transduction and membrane transport. Analysis of IC 50 and gene expression levels for 1 3 4 cisplatin-treated bladder cancer cell lines confirmed these relationships evident from GI 50 1 3 5 values of different breast cancer lines. IC 50 values were related to GE for CFLAR, 1 3 6 FEN1, MAPK3, MSH2, NFKB1, PNKP, PRKAA2, and PRKCA 20 . Similarly, separate 1 3 7 bladder cell line IC 50 values from the Genomics of Drug Sensitivity in Cancer project 1 3 8 (http://www.cancerrxgene.org; N=17) were correlated with GE for CFLAR, FEN1, and 1 3 9 NFKB1, in addition to ATP7B, BARD1, MAP3K1, NFKB2, SLC31A2 and SNAI1. 1 4 0
We performed MFA on the GI 50 values for cisplatin, carboplatin and oxaliplatin, 1 4 1 without consideration of either GE or CN. Responses to cis-and carboplatin were 1 4 2 directly correlated (a 6.2º separation between vectors), but neither was related to the 1 4 3 oxaliplatin response ( Figure 2 SVM generated from 17 bladder cancer cell lines in cancerRxgeneresulted in 2 equally 1 5 5 accurate signatures (with 11.8% misclassification) consisting of either PNKP and 1 5 6 PRKCA or ATP7B, CFLAR, FEN1, MAPK3, NFKB1 and SLC22A11. These models were 1 5 7 not useful for predicting patient outcomes due to the limited size of the training set 1 5 8 GI 50 -Threshold Independent Modeling 1 5 9
In our previous studies, we set median GI 50 value as the threshold to 1 6 0 distinguished drug resistance and sensitivity 5,6 . An important question is whether the 1 6 1 genes contributing to drug response are consistent among different cell lines, each with 1 6 2 their own unique GI 50 values. Different ML models were obtained by shifting the GI 50 1 6 3 threshold, which changed the labels of resistant vs. sensitive cell lines. After feature 1 6 4 selection, the compositions of the corresponding gene signatures for each threshold 1 6 5 were compared. Finally, ensemble averaging of all of these optimized Gaussian SVM 1 6 6 models derived for different GI 50 thresholds was used to create a threshold-independent 1 6 7 ML-based signature. 1 6 8
Kinase (MAPK3, MAP3K1) genes and apoptotic family members (BCL2, 1 6 9 BCL2L1) were most the common in the cisplatin signatures at different GI 50 thresholds, 1 7 0 with consistent representation of error-prone and base-excision DNA repair genes as 1 7 1 well ( Figure 3A ; Supplementary Table S2A ). The kinases are more concentrated in 1 7 2 signatures with lower drug sensitivity thresholds, whereas BCL2 and BCL2L1 are more 1 7 3 ubiquitous at all levels. The error prone polymerases, POLD1 and POLQ, are more 1 7 4 frequent in models with lower sensitivity thresholds, while the flap endonuclease FEN1 1 7 5 tends to be present at high levels of resistance. Thresholded models for carboplatin-1 7 6 related genes commonly contained the apoptotic family member AKT1, transcription 1 7 7 regulation genes ETS2 and TP53, as well as cell growth factors VEGFB and VEGFC, 1 7 8 although the latter was less common at lower sensitivity thresholds ( Figure 3B ). 1 7 9
Common oxaliplatin-related genes included transporters SLCO1B1 and GRTP1 (but not 1 8 0 SLC47A1), transcription genes NFE2L2, PARP15 and CLCN6, as well as multiple 1 8 1 metabolism-related genes ( Figure 3C ). 1 8 2 SVM models were also derived using the cisplatin and/or carboplatin-treated 1 8 3 TCGA (The Cancer Genome Atlas) bladder urothelial carcinoma patients, using post-1 8 4 treatment time to recurrence as a surrogate for different resistance thresholds (similarly 1 8 5 performed in Mucaki et al. [2017] 24 ; Supplementary Table S3 ). Similar trends to cell line 1 8 6
SVMs are apparent; POLQ is frequently selected when the resistance threshold is set at 1 8 7 a longer time period, while FEN1 appears when it is shorter. However BCL2, which is 1 8 8 present in a majority of breast cancer cell line SVMs, is present in only one model 1 8 9 derived from TCGA data. Similarly, MSH2 was rarely selected using cell lines, yet 1 9 0 appears in nearly all patient derived SVMs with > 1 year recurrence. 1 9 1 1 0 respectively. Each model was validated using available platin-treated patient datasets 25-1 9 4 29 . The chemotherapy response metadata differed between studies. Als et al. 28 reported 1 9 5 survival post-treatment, whereas Tsuji et al. 29 categorized patients as responders and 1 9 6 non-responders. TCGA provided two different measures which were used to assess 1 9 7 predictive accuracy in our models -chemotherapy response and disease-free survival. 1 9 8
Accuracy is similar using either measure ( Supplementary Table S4A ); however 1 9 9 recurrence and disease-free survival was used as the primary measure of response as it 2 0 0 was more often recorded in the TCGA data sets tested. Patients from Als et al. with a ≥ 2 0 1 5 year survival post-treatment were labeled as sensitive to treatment. The differences 2 0 2 between these metadata may, in part, account for the differences in the prediction 2 0 3 accuracy of the thresholded SVM models.
0 4
At higher resistance thresholds for any platin drug (low GI 50 ), where more cell 2 0 5 lines are labeled sensitive, the positive class (disease-free survival) is correctly 2 0 6 classified, while the negative class (recurrence) is highly misclassified (Suppl. Figures 1 2 0 7
and 2). The reverse is true for models built using lower resistance thresholds (high GI 50 ). 2 0 8
We therefore state SVMs generated at these extreme thresholds are not very useful at 2 0 9 predicting patient data. When used to predict recurrence in the TCGA datasets, 2 1 0 sensitivity and specificity appears to be maximized in models where the GI 50 threshold 2 1 1 for resistance was set near (but not necessarily at) the median (Suppl. Figure 1 To evaluate the consistency in the prediction of TCGA bladder cancer patients 2 4 7 treated with cisplatin, the predicted distance from the hyperplane for all SVMs generated 2 4 8 were plotted for each patient with a short recurrence time (<6 mo., N=10; Supplementary 2 4 9 Figure 3 ). Despite showing similar levels of resistance to treatment, patterns differed 2 5 0 between patients. While these patients would be expected to be indicated as highly 2 5 1 1 3
Suppl. Table S6C ). As in cisplatin, limiting this analysis to oxaliplatin SVM models with 2 7 0 moderate GI 50 thresholds did not significantly increase accuracy. 2 7 1
To determine the impact of individual genes on overall model accuracy, each 2 7 2 gene within every SVM model was excluded, and model accuracy was reassessed 2 7 3 ( Supplementary Table S2A ; S2B and S2C contain carbo-and oxaliplatin models, 2 7 4 respectively). Genes which consistently significantly increase misclassification 2 7 5 (averaging > 16% increase) in moderate threshold SVMs (GI 50 thresholds set from 5.1 to 2 7 6 5.5) include ERCC2, POLD1, BARD1, BCL2, PRKCA and PRKCB. ERCC2 and POLD1 2 7 7 perform critical functions in nucleotide and base excision repair, respectively. PRKCA 2 7 8
and PRKCB are paralogs with significant roles in signal transduction. BARD1 has been 2 7 9
shown to reduce apoptotic BCL2 in the mitochondria 30 , and has a key role in genomic 2 8 0 stability through its association with BRCA1. Genes with a high variance in increased 2 8 1 misclassification between different models include NFKB1, NFKB2, TWIST1, TP63, 2 8 2 PRKAA2, and MSH2. The variance of these genes may be due to epistatic interactions 2 8 3 with other biological components, including the other genes in the SVM. For example, 2 8 4 NFKB1 and NFKB2 are jointly included in 7 SVMs generated at a moderate GI 50 2 8 5 threshold. There is evidence of possible epistasis in that the removal of either of these 2 8 6 genes, but not necessary both, will have a large impact in model misclassification rates 2 8 7 (≥ 18.0% increase). The misclassification variance of NFKB1 with NFKB2, is significantly 2 8 8 lower than in SVM models lacking NFKB2. 2 8 9
Predicting cisplatin response in patients based on smoking history 2 9 0
Tobacco smoking is known as the highest risk factor for the development of 2 9 1 bladder cancer 31 . We therefore subdivided the patients based on their smoking history 2 9 2 and tested the thresholded models ( Supplementary Tables S7 and S8 ). When testing 1 4 patients who were lifelong non-smokers, the prediction accuracy of Cis1 predicted all 2 9 4 non-smoking patients who were recurrent after 18 months as cisplatin-resistant (N=5). 2 9 5
Prediction accuracy for disease-free patients was 57.1% (N=14). Another model (Cis18; 2 9 6
Suppl. Table S7 ) had performed equally as well for non-smokers, and these two models 2 9 7 share 7 genes : BCL2, BCL2L1, FAAP24, MAP3K1, MAPK13, MAPK3 , and SLC31A2. 2 9 8
Threshold independent analysis predicted disease-free equally well, but recurrence was 2 9 9 less accurate (66.7%). Note that non-smokers make up a small subset of the patients 3 0 0 tested (N=19). Threshold-independent prediction of recurrence in patients with a 3 0 1 smoking history was 46% accurate (N=13), while disease-free patients were correctly 3 0 2 predicted at a rate of 58% (N=19). Recurrence in these patients was best predicted by a 3 0 3 model built at the median GI 50 threshold (Cis2). Accuracy improved for both disease-free 3 0 4 (57.7% -> 61.9%) and recurrent patients (76.0% -> 78.6%) when excluding patients who 3 0 5 quit smoking more than 15 years before diagnosis. Genes in this SVM which are not 3 0 6 present in the two models which performed well for non-smokers include CFLAR and 3 0 7 PRKAA2. 3 0 8
Tobacco smoking has a significant impact on cytosine methylation levels in the 3 0 9 genome 32 . CpG island methylation has been associated with smoking pack years in a 3 1 0 subset of the TCGA bladder urothelial carcinoma patients 25 . We suspected that the level 3 1 1 of methylation measured in t SVMs which performed best for smoking and non-smoking 3 1 2 patients might differ, and with possible concomitant effects on GE. When ranking each 3 1 3 gene from Cis1 by highest methylation and GE, 88 of 1080 patient: gene combinations 3 1 4 showed the expected inverse correlation between methylation levels and GE (i.e. high 3 1 5 methylation and low GE). Inverse correlation of methylation and GE was more common 3 1 6 than direct correlation (i.e. high methylation and high GE; N=17). However, direct 3 1 7 correlation was more common in patients with a recent smoking history (70.5%). This 3 1 8 pattern was also observed for Cis2, which best predicted recurrence in smokers. In 3 1 9 cases where methylation and GE are directly correlated, we propose that smoking may 3 2 0 alter expression by other effects, eg. mutagenic, rather solely than by epigenetic 3 2 1 inactivation through methylation. 3 2 2
To determine which genes in these models led to discordant predictions of 3 2 3 patient outcome, we conducted a bioinformatic experiment to gradually alter the 3 2 4 expression of each signature gene until the misclassification was corrected. If the GE 3 2 5 value required to cross this threshold exceeded ≥ 3-fold the highest/lowest expression of 3 2 6 that gene, it was interpreted as a minor contributor to the prediction. Genes which could 3 2 7 not correct a discordant prediction included PRKAA2, NFKB1, NFKB2 and TWIST1. 3 2 8
Significant genes which, when altered, corrected discordant predictions included 3 2 9 MAP3K1, MAPK3, SLC22A5 and SLC31A2. Altering BCL2L1 expression was more 3 3 0 likely to correct the discordant predictions of Cis1 (4 out of 5) than with Cis2 (2 out of 4). 3 3 1 DISCUSSION 3 3 2
Using gene expression signatures, we derived both GI 50 threshold-dependent 3 3 3 and -independent ML models which predict the chemotherapy responses for cisplatin, 3 3 4 carboplatin and oxaliplatin, respectively. The cisplatin model Cis1 ( Supplementary Table  3 3 5 S5A) most accurately predicted response in bladder cancer patients after 18 months, 3 3 6
and Car1 (Suppl . Table S5B ) best predicted response in ovarian cancer patients after 4 3 3 7 years. Oxa1 (Suppl . Table S5C ) more accurately predicted disease-free patients than 3 3 8 recurrent disease at the one year treatment threshold. The thresholds which best 3 3 9
represented time-to-recurrence differed between the platin drugs in each cancer type. 3 4 0 1 6
The three platin drugs produce distinctly different gene signature models. Initial 3 4 3 gene sets exhibited some overlap between platin drugs (N=67 between any two platins), 3 4 4 but very few of these were correlated by MFA of GI 50 with multiple platin drugs (ATP7B, 3 4 5 BCL2 and MSH2). Despite the close similarity between cisplatin and carboplatin GI 50 3 4 6 response (see Figure 2 ), only one gene (ATP7B) was related by MFA to GI 50 levels of 3 4 7 both drugs. BCL2 and MSH2 correlated with both cisplatin and oxaliplatin GI 50 . The 3 4 8 increase in misclassification caused by the elimination of MSH2 from any SVM model in 3 4 9 which it was present was significant; for example, in oxaliplatin model Oxa21 (Suppl. 3 5 0 increased by 19.1% and 28.2%, respectively. These differences may reflect the 3 5 2 spectrum of activity, sensitivity, and toxicity of these signature genes [21] [22] [23] 33, 34 . 3 5 3
Gene signature models derived from cell lines and tested on patients differ in 3 5 4 their outcome measures. The exact GI 50 cell line threshold that is most predictive of 3 5 5 patient outcome is not known, and different groups use different methods to discretize 3 5 6
GI 50 values 35, 36 . Therefore, we developed ML models for platin drugs which predict drug 3 5 7 response without relying on arbitrary GI 50 thresholds. For cisplatin, SVM ensemble 3 5 8 averaging generated on different resistance thresholds shows a small increase in 3 5 9 1 7 with poor performance and overfitting by combining models that individually perform 3 6 7 slightly better than chance 37 . 3 6 8
It is difficult to reconcile gene signatures without features known to be related to 3 6 9 chemoresistance with tumor biology. Our thresholding approach may reveal potentially 3 7 0 important genes and pathways associated with platin resistance. It would be preferable 3 7 1 to explore pathways related to signature genes to improve accuracy, identify potential 3 7 2 targets for further study of chemoresistance, and expand the model parameters to take 3 7 3 into account alternate states besides those captured in the original signature 38 . 3 7 4
Signatures for resistance may be useful for developing targeted intervention to re-3 7 5 sensitize tumours. For example, the mismatch repair (MMR) gene MSH2 is commonly 3 7 6 present in gene signatures at high resistance levels for oxaliplatin, which is of interest, 3 7 7 as MMR deficiency has been shown to be predictive for oxaliplatin resistance 34 . Indeed, 3 7 8 MLH1, MSH2 and MSH6-deficient cells are more susceptible to oxaliplatin, despite 3 7 9
MMR-deficiency being associated with cisplatin resistance 33 . The autoimmune disease-3 8 0 associated gene SIAE, which has been previously shown to have a strong negative 3 8 1 correlation to oxaliplatin response in advanced CRC patients 39 , was selected in the 3 8 2 majority of thresholded oxaliplatin models ( Supplementary Table S2C ). The gene BCL2, 3 8 3 which was commonly selected for cisplatin ( Figure 3A) , was rarely selected for 3 8 4 oxaliplatin (Figure 3C) . At the highest levels of resistance to cisplatin, models were 3 8 5 enriched for genes belonging to DNA repair, anti-oxidative response, apoptotic pathways 3 8 6 and drug transporters ( Figure 3A) . These gene pathways are known to be involved in 3 8 7 cisplatin resistance 40,41 and these specific genes may be explored in subsequent work to 3 8 8 identify the contribution to chemotherapy response in a biochemical context. 3 8 9
It may be feasible to predict responses to combination chemotherapy with the methotrexate, vinblastine, and doxorubicin, which comprise the MVAC cocktail used to 1 9 improved by data normalization. In this study, datasets were subjected to z-score 4 1 7 normalization. In subsequent studies, other techniques to correct for some of these 4 1 8 effects have been described and could be applied 42 . 4 1 9
In summary, we describe GI 50 -or IC 50 -threshold-independent ML models to 4 2 0 predict chemotherapy response to platin agents in cancer patients. Ensemble machine 4 2 1 learning produced combined signatures that were more accurate than most individual 4 2 2 models generated with different thresholds. Genes associated cisplatin response 4 2 3 included those which exacerbate resistance in patients with a history of smoking. The 4 2 4 methodology described here should be adaptable to other drugs and cancer types. With 4 2 5 a range of models for multiple drugs, it may be possible to improve the efficacy of 4 2 6 treatment by tailoring treatment to a patient's specific tumour biology, and reduce 4 2 7 treatment duration by limiting the number of different therapeutic regimens prescribed 4 2 8 before achieving a successful response 43 Maximization [RSEM] is < 5.0 for majority of individuals). The final gene sets were 4 5 1 chosen using MFA to analyze interactions between GE, CN, and GI 50 data for the drug 4 5 2 of interest 47 . Genes whose GE and/or CN showed a direct or inverse correlation with 4 5 3 GI 50 were selected for SVM training. This reduces the overall number of genes for SVM 4 5 4 analysis, and thus helps to avoid a data to size sample imbalance. For cisplatin, MFA 4 5 5 was repeated using IC 50 values for 17 bladder cancer cell lines; however, the available 4 5 6 CN data generally showed a lack of variation in the cell lines for these genes. Toolbox in MATLAB 48 using Gaussian kernel functions (fitcsvm), and then tested with a 4 6 9
leave-one-out cross-validation (using 'crossval' and 'leaveout' options) . A greedy 4 7 0 backwards feature selection algorithm was used to improve classification accuracy 50 . 4 7 1
The gene subset with the lowest misclassification with cross-validation is selected as the 4 7 2 model for subsequent testing with patient GE and clinical data. 4 7 3
Derivation of gene signatures for different drug resistance thresholds 4 7 4
We have previously set a conventional GI 50 threshold distinguishing sensitivity 4 7 5 from resistance at the median of the range of drug concentrations that inhibited cell 4 7 6 growth by 50% 6 . We hypothesized that different gene signatures could be derived for 4 7 7 different levels of drug resistance by varying this threshold. ML experiments for 4 7 8 classifying resistance or sensitivity at GI 50 values generated a series of optimized 4 7 9
Gaussian SVM models whose performance were assessed with patient expression data 4 8 0 for each signature. A heat map which illustrates the frequencies of genes appearing in 4 8 1 these models was created with the R language hist2d function. 
